What TheWell Bioscience does

TheWell Bioscience, founded in 2015 and headquartered in Monmouth Junction, New Jersey, is a privately-held biotechnology company (1–10 employees) that develops and sells a proprietary xeno-free (animal origin-free) hydrogel platform for 3D cell culture. Its core product family, VitroGel, is a synthetic, biofunctional extracellular matrix mimic offered in ready-to-use formulations (ORGANOID, STEM, MSC, HEK293, NEURON, EMT) and tunable variants with mechanical stiffness from 10 to 20,000+ Pa and functional ligands (RGD, COL, MMP, IKVAV, YIGSR). The platform is complementary with VitroINK bioinks for 3D bioprinting, RocketCell xeno-free media for organoids/iPSCs/NSCs/hMSCs, CytoGrow recombinant growth factors, VitroPrime culture plates engineered for 3D workflows, and Cyto3D live-dead assay kits, forming an end-to-end xeno-free workflow across hydrogel, media, growth factor, vessel, and downstream analysis layers.

Revenue is generated through three streams: (1) direct sales of consumable products (hydrogels, bioinks, media, growth factors, plates, assay kits) via an e-commerce storefront and direct phone/email ordering with quote-based (non-public) pricing; (2) global distribution through Sartorius Group, which acquired a minority equity stake in April 2024 alongside a cooperation agreement; and (3) international sales through a regional distributor network listed on the company website. Custom solutions services provide additional professional-services revenue for specialized research needs. The company sells to academic researchers (e.g., University of Graz, University of Manchester, Temple University), pharmaceutical/biotech drug discovery teams, stem cell and cell-therapy biomanufacturers, lab-automation/high-throughput screening users, and 3D bioprinting researchers, with adoption evidenced by 370+ peer-reviewed publications citing the products.

Name

TheWell Bioscience

Legal name

TheWell Bioscience Inc.

Website

https://thewellbio.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

TheWell Bioscience is a privately-held New Jersey biotech that develops and sells an end-to-end xeno-free 3D cell culture platform, including VitroGel hydrogels, VitroINK bioinks, RocketCell media, CytoGrow growth factors, VitroPrime plates, and Cyto3D assays, serving academic researchers, pharma/biotech drug discovery teams, and cell-therapy biomanufacturers globally via direct sales, distribution partners, and a Sartorius global distribution partnership.

Ownership category

akta.pro rank

Product category

3D Cell Culture Reagents

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)

akta.pro secondary industries

Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD), Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

Keywords

• Xeno-free hydrogels
• 3D cell culture reagents
• Organoid culture media
• Biofunctional bioinks
• Cell culture plates

Headquarters

HQ city

North Brunswick

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Hydrogel and Bioink Product Sales: TheWell Bioscience generates revenue primarily through the direct sale of its proprietary xeno-free hydrogel products (VitroGel®), bioinks (VitroINK®), culture media (RocketCell™), culture vessels (VitroPrime™), growth factors (CytoGrow™), assay kits, and cell recovery solutions. Products are sold via e-commerce, direct sales, and distributor networks globally.
2. Distribution Agreement Revenue (Sartorius): Sartorius Group distributes TheWell Bioscience's products globally under a cooperation agreement, providing TheWell with expanded market reach and revenue from distribution arrangements.
3. Custom Solutions Services: The company offers custom solutions services for specialized research needs, indicating revenue from service engagements alongside product sales.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Core offering

TheWell Bioscience develops, manufactures, and sells an end-to-end, xeno-free (animal origin-free) 3D cell culture platform built around its proprietary VitroGel® biofunctional hydrogel technology. The product portfolio spans hydrogels (VitroGel®), 3D bioprinting bioinks (VitroINK®), xeno-free culture media (RocketCell™), recombinant growth factors (CytoGrow™), culture plates and vessels (VitroPrime™), live/dead assay kits (Cyto3D®), cell/organoid recovery solutions, and assay kits for angiogenesis, cell invasion, and glioblastoma research.

Product overview

TheWell Bioscience offers an end-to-end, xeno-free 3D cell culture platform consisting of multiple integrated product families. The core offering centers on VitroGel® hydrogels—a range of animal-free, biofunctional hydrogel systems for 3D cell culture available in ready-to-use and tunable formulations. Complementary products include VitroINK® bioinks for 3D bioprinting, RocketCell™ xeno-free culture media for diverse cell types (organoids, iPSCs, NSCs, hMSCs), CytoGrow™ recombinant growth factors and proteins, VitroPrime™ culture plates and vessels optimized for 3D workflows, and Cyto3D® downstream analysis reagents. The platform is designed for applications including organoid culture, stem cell scale-up, cancer research, drug discovery, lab automation, and biomanufacturing. The company positions itself as an all-in-one xeno-free biofunctional platform for precision medicine, cell therapy, and biomanufacturing.

Differentiator

Problem solved

Functional benefit

Brands

• VitroGel®: Xeno-free biofunctional hydrogel system for 3D cell culture applications including organoids, stem cells, and bioprinting
• VitroINK®
• RocketCell™
• VitroPrime™
• CytoGrow™
• Cyto3D®

Products and services

• VitroGel® Hydrogel System Xeno-free, biofunctional hydrogel matrix that mimics natural extracellular matrix for 3D cell culture. Available in ready-to-use variants (ORGANOID, STEM, MSC, HEK293, NEURON, EMT) and tunable variants (3D, RGD, COL, MMP, IKVAV, YIGSR) with adjustable mechanical strength and functional ligands. Enables 3D cell culture assays in less than 20 minutes.
• VitroINK® Bioinks Xeno-free, biofunctional bioink for 3D bioprinting that prints without UV, heat curing, or chemical cross-linking. Available in multiple functional ligand variants (3D, RGD, COL, MMP, IKVAV, YIGSR) with corresponding starter kits, mixing kits, nozzle tips, and needle tips.
• RocketCell™ Xeno-Free Culture Media Portfolio of xeno-free 3D cell culture media supporting diverse cell culture applications including organoids, iPSCs, NSCs, and hMSCs. Includes specialized media for organoid culture, iPSC expansion and differentiation, MSC culture, and neural stem cell applications.
• CytoGrow™ Recombinant Growth Factors and Proteins Portfolio of premium-grade recombinant proteins including growth factors (EGFs, FGFs, PDGFs, TGFs, VEGFs, IGFs, interferons, interleukins), extracellular matrix proteins (fibronectin, vitronectin), and accessory proteins for cell culture applications requiring bioactivity and lot-to-lot consistency.
• VitroPrime™ Culture Plates and Vessels

Quantifiable outcome

• Complete ECM dissociation within 2 minutes with VitroGel Organoid Recovery Solution vs. over an hour for conventional alternatives
• +3 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles5 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Six partnerships are on record, tiered core and minor.

• PeptiGrowth Inc.coreGTM or Marketing Partner · 7 January 2026TheWell Bioscience and PeptiGrowth entered into a Marketing Collaboration Agreement to jointly promote complementary cell culture technologies. The partnership combines TheWell's xeno-free VitroGel® hydrogel system with PeptiGrowth's synthetic peptide growth factors to offer a complete xeno-free workflow solution for researchers and biomanufacturers in global life science markets.
• Sartorius GroupcoreChannel Partner/ Reseller/ Distributor · 9 April 2024Sartorius Group entered into a cooperation agreement and minority shareholding investment in TheWell Bioscience. Under the agreement, Sartorius distributes TheWell Bioscience's animal-free hydrogels and bioinks globally, aiming to improve predictions in drug discovery. The partnership combines Sartorius's global distribution reach with TheWell's xeno-free hydrogel technology. Legal advisory was provided by Hogan Lovells for the cross-border transaction.
• Dr. Eva Roblegg's Group, University of GrazminorStrategic or Co-development PartnerAcademic research collaboration where Dr. Roblegg's group at the University of Graz used VitroGel® to develop an advanced in vitro vascularized intestinal model including macrovascular endothelium, published in Molecular Pharmaceutics.
• Breast Biology Group, University of ManchesterminorStrategic or Co-development PartnerAcademic collaboration with the Breast Biology Group at the University of Manchester's Breast Centre to develop a novel preclinical explant model of the normal human breast using VitroGel® RGD, funded by Prevent Breast Cancer and published in the Journal of Mammary Gland Biology and Neoplasia.
• PAL Lab, Temple UniversityminorStrategic or Co-development PartnerThe PAL Lab at Temple University, led by Ajay Pal, Ph.D., initiated research on VitroGel® NEURON for spinal cord injury repair applications.
• Hogan LovellsminorOthersHogan Lovells provided legal advisory services to Sartorius Group for the cooperation agreement and minority shareholding in TheWell Bioscience, handling multiple legal and strategic considerations for the cross-border transaction.

Scale indicators4 records

Recent moves5 records

Expansion highlights6 records

Broad incumbents

• Corning Incorporated: Corning manufactures Matrigel, the dominant animal-derived ECM benchmark that TheWell's VitroGel platform directly competes against in 3D cell culture and organoid applications. Comparable because Corning also produces plastic labware, cell culture vessels, and bioprocess consumables, serving overlapping pharma and academic customers.
• Thermo Fisher Scientific: Thermo Fisher offers Gibco cell culture media, growth factors, and 3D culture reagents across its life sciences portfolio. Comparable because it sells overlapping reagents and consumables to the same pharma, biotech, and academic researchers that TheWell targets, with far broader bundling and distribution leverage.
• Merck KGaA (MilliporeSigma): MilliporeSigma supplies ECM hydrogels, cell culture media, and bioprocess reagents under the Sigma-Aldrich brand. Comparable because it serves the same 3D cell culture, organoid, and cell therapy manufacturing markets with a much larger commercial and regulatory footprint.

Direct peers

• STEMCELL Technologies: STEMCELL Technologies develops specialized cell culture media, reagents, and tools for stem cell, organoid, and immunology research. Comparable because it targets the same life sciences researcher customer base with overlapping product categories (media, matrices, differentiation kits) and competes head-to-head with RocketCell and VitroGel.
• BICO (CELLINK): BICO, through CELLINK and its subsidiaries, provides bioinks, 3D bioprinters, and tissue engineering consumables. Comparable because it offers VitroINK's direct competition in xeno-free bioinks and operates in overlapping 3D bioprinting and tissue engineering customer segments.
• Advanced BioMatrix: Advanced BioMatrix manufactures collagen-based, hyaluronic acid, and synthetic ECM hydrogels for 3D cell culture and bioprinting. Comparable because it sells directly overlapping hydrogel and bioink products targeting the same 3D cell culture and tissue engineering researchers.
• Reprocell: Reprocell provides stem cell products, 3D cell culture reagents, and custom bioassay services to pharma and academic researchers. Comparable because it sells directly competing cell culture matrices and reagents to the same iPSC, organoid, and drug discovery customer segments.

Emerging players

• TissUse: TissUse develops multi-organ-on-chip and microphysiological systems for drug testing and disease modeling. Comparable because it serves overlapping preclinical researchers using 3D cell models and complements or competes with organoid-based workflows that VitroGel enables.
• Organovo Holdings: Organovo develops 3D bioprinted human tissue models for drug discovery and therapeutic applications. Comparable because it operates in the 3D bioprinting and tissue engineering space served by VitroINK and intersects with TheWell's organoid and tissue modeling customer base.

Others

• PeptiGrowth: PeptiGrowth develops synthetic peptide growth factors for cell culture and regenerative medicine. Comparable as an ecosystem partner through the 2026 marketing collaboration with TheWell, addressing overlapping stem cell and cell therapy manufacturing customers seeking a fully xeno-free workflow.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/thewell-bioscience
• Instagraminstagram.com/thewellbio
• Xx.com/thewellbio
• Facebookfacebook.com/thewell-bioscience-1118000958253256

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TheWell Bioscience